RAF1 and cancer: Considering the importance of c-Raf for the survival of cancer cells in vitro and in vivo, numerous Raf inhibitors have been developed and successfully exploited in the clinic, such as Sorafenib [18] or Regorafenib [19], whilst selective c-Raf inhibitors is still undergoing preclinical and clinical evaluation [20, 21].